🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Teri Kreisl

ORCID: 0000-0002-3710-022X
Biochemistry, Genetics and Molecular BiologyMedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Papers

Driven by 6 papers — median percentile 80. Top paper: “177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial”.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2
N/A
4.3DataRank · unranked
287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3567
N/A
0DataRank · unranked
1 citations

Veena Singh, Shing Mirn Lee, David Cieremans, Andrew B. Lassman, Dawn L. Hershman +12 more

Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas

Neurology(2021)10.1212/wnl.0000000000013057
N/A
0DataRank · unranked
26 citations

Craig D. Blinderman, Fábio M. Iwamoto, Teri Kreisl, Mary Welch, Yazmín Odia +5 more

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab186
N/A
0DataRank · unranked
4 citations

Claudia R. Oliva, Christopher S. Coffey, Merit Cudkowicz, Robin Conwit, Anna Gudjonsdottir +28 more

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.03.462951
N/A
0DataRank · unranked
7 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +48 more